Leon H. Charney Division of Cardiology, New York University Grossman School of Medicine, New York, NY (C.J.M.v.O., G.C., M.Z., M.D., M.C.).
Rocket Pharmaceuticals, Inc, Cranbury, NJ (B.N., C.B.S., K.M.S., V.M., E.F., D.R., P.Y., J.S., C.D.H.).
Circ Genom Precis Med. 2024 Feb;17(1):e004305. doi: 10.1161/CIRCGEN.123.004305. Epub 2024 Jan 30.
Pathogenic variants in PKP2 (plakophilin-2) cause arrhythmogenic right ventricular cardiomyopathy, a disease characterized by life-threatening arrhythmias and progressive cardiomyopathy leading to heart failure. No effective medical therapy is available to prevent or arrest the disease. We tested the hypothesis that adeno-associated virus vector-mediated delivery of the human gene to an adult mammalian heart deficient in PKP2 can arrest disease progression and significantly prolong survival.
Experiments were performed using a PKP2-cKO (cardiac-specific, tamoxifen-activated PKP2 knockout murine model). The potential therapeutic, adeno-associated virus vector of serotype rh.74 (AAVrh.74)-PKP2a (PKP2 variant A; RP-A601) is a recombinant AAVrh.74 gene therapy viral vector encoding the human PKP2 variant A. AAVrh.74-PKP2a was delivered to adult mice by a single tail vein injection either before or after tamoxifen-activated PKP2-cKO. PKP2 expression was confirmed by molecular and histopathologic analyses. Cardiac function and disease progression were monitored by survival analyses, echocardiography, and electrocardiography.
Consistent with prior findings, loss of PKP2 expression caused 100% mortality within 50 days after tamoxifen injection. In contrast, AAVrh.74-PKP2a-mediated PKP2a expression resulted in 100% survival for >5 months (at study termination). Echocardiographic analysis revealed that AAVrh.74-PKP2a prevented right ventricle dilation, arrested left ventricle functional decline, and mitigated arrhythmia burden. Molecular and histological analyses showed AAVrh.74-PKP2a-mediated transgene mRNA and protein expression and appropriate PKP2 localization at the cardiomyocyte intercalated disc. Importantly, the therapeutic benefit was shown in mice receiving AAVrh.74-PKP2a after disease onset.
These preclinical data demonstrate the potential for AAVrh.74-PKP2a (RP-A601) as a therapeutic for PKP2-related arrhythmogenic right ventricular cardiomyopathy in both early and more advanced stages of the disease.
PKP2(桥粒斑蛋白 2)中的致病变异可导致致心律失常性右室心肌病,这是一种以危及生命的心律失常和进行性心肌病导致心力衰竭为特征的疾病。目前尚无有效的药物治疗方法可用于预防或阻止疾病进展。我们假设腺相关病毒载体介导的人类基因递送至 PKP2 缺陷的成年哺乳动物心脏,可以阻止疾病进展并显著延长生存时间。
实验使用了 PKP2-cKO(心脏特异性,他莫昔芬激活的 PKP2 敲除鼠模型)。潜在的治疗性腺相关病毒载体血清型 rh.74(AAVrh.74)-PKP2a(PKP2 变异 A;RP-A601)是一种重组 AAVrh.74 基因治疗病毒载体,编码人类 PKP2 变异 A。AAVrh.74-PKP2a 通过单次尾静脉注射递送至成年小鼠体内,在他莫昔芬激活 PKP2-cKO 之前或之后进行。通过分子和组织病理学分析确认 PKP2 表达。通过生存分析、超声心动图和心电图监测心脏功能和疾病进展。
与之前的发现一致,在他莫昔芬注射后 50 天内,PKP2 表达缺失导致 100%的死亡率。相比之下,AAVrh.74-PKP2a 介导的 PKP2a 表达导致 >5 个月的 100%存活率(在研究结束时)。超声心动图分析显示,AAVrh.74-PKP2a 可防止右心室扩张,阻止左心室功能下降,并减轻心律失常负担。分子和组织学分析显示,AAVrh.74-PKP2a 介导的转基因 mRNA 和蛋白表达以及适当的 PKP2 在心肌闰盘处的定位。重要的是,在疾病发作后接受 AAVrh.74-PKP2a 治疗的小鼠中显示出了治疗益处。
这些临床前数据表明,AAVrh.74-PKP2a(RP-A601)具有治疗 PKP2 相关致心律失常性右室心肌病的潜力,无论是在疾病的早期还是更晚期阶段都有治疗作用。